Side-by-side comparison of AI visibility scores, market position, and capabilities
Waukesha WI home generator and clean energy (NYSE: GNRC) ~$3.7B FY2024 revenue; 75% US residential standby share, PWRcell battery storage, grid reliability tailwind competing with Kohler and Tesla Powerwall.
Generac Holdings Inc. is a Waukesha, Wisconsin-based power generation and energy technology company — publicly traded on the New York Stock Exchange (NYSE: GNRC) as an S&P 500 Industrials component — manufacturing and distributing residential and commercial standby generators, portable generators, pressure washers, light towers, industrial natural gas generators, and residential clean energy systems (battery storage, solar inverters, EV chargers) through approximately 8,500 employees at manufacturing facilities in Wisconsin, South Carolina, Mexico, and international plants. In fiscal year 2024, Generac reported revenues of approximately $3.7 billion, recovering from the 2022-2023 inventory correction cycle — where pandemic-era demand surge for residential standby generators (driven by Texas Winter Storm Uri in 2021, California wildfire public safety power shutoffs, and COVID-era home improvement spending) had created channel inventory overstocking that reduced dealer reorders through 2022-2023 even as manufacturing continued. CEO Aaron Jagdfeld's strategy of expanding beyond home standby generators into residential clean energy (Generac's PWRcell battery storage system, PWRmicro microinverter, PWRlink EV charger — positioning Generac as the whole-home energy management platform for energy-resilient households) accelerated with the 2023 acquisition of CleanCast Solar and continued deployment of the ecobee smart thermostat integration with Generac's PWRmanager energy monitoring system. The residential power resilience market has expanded beyond traditional generator buyers (homeowners in hurricane, ice storm, or blackout-prone areas) to a broader clean energy consumer who values solar+storage energy independence and backup power as grid reliability declines in wildfire and extreme weather-affected regions.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.